Method and composition for leucyl-tRNA synthetases and derivatives thereof that activate and aminoacylate non-leucine amino acid to tRNA adaptor molecules
A method and composition for tRNA synthetases that activate and aminoacylate nonstandard and noncognate amino acids to tRNA adaptor molecules is described that can be used to generate custom designed protein products for uses in medicinal, therapeutic, diagnostic, biotechnology, engineering, and spectroscopy applications. Some tRNA synthetases naturally misactivate and misaminoacylate noncognate amino acids. Many of these tRNA synthetases, including but not limited to leucyl-, isoleucyl-, and valyl-tRNA synthetases, have evolved proofreading and editing mechanisms to correct these mistakes. Inactivation of the enzyme's editing activity allows and facilitates production and accumulation of tRNAs that are misaminoacylated with nonstandard and noncognate amino acids. These misaminoacylated tRNAs can be used to introduce novel amino acids into proteins.
1. A method for producing a mutated leucyl-tRNA synthetase that misaminoacylates non-leucine amino acids comprising the steps of:
mutating one to three amino acids in a conserved editing active site region of a connective polypeptide 1 domain of a leucyl-tRNA synthetase, wherein the conserved editing active site region is selected from the group consisting of a threonine-rich region at a position corresponding to amino acids 247 to 257 relative to the E. coli leucyl-tRNA synthetase numbering and a region surrounding a conserved aspartic acid corresponding to amino acid 345 including seven amino acids preceding amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering, and combinations thereof, wherein mutating the one to three amino acids inactivates editing activity of the leucyl-tRNA synthetase and produces a mutated leucyl-tRNA synthetase that misaminoacylates non-leucine amino acids; and
aminoacylating a tRNA molecule with the mutated leucyl-tRNA synthetase in the presence of at least one non-leucine amino acid, thereby aminoacylating the non-leucine amino acid onto the tRNA molecule, wherein the non-leucine amino acid is an amino acid activated by the mutated leucyl-tRNA synthetase.
2. The method of claim 1 , wherein mutating includes mutating a threonine at a position corresponding to amino acid 252 relative to the E. coli leucyl-tRNA synthetase numbering.
3. The method of claim 2 , wherein the threonine is mutated to a phenylalanine.
4. The method of claim 2 , wherein the threonine is mutated to a tyrosine.
5. The method of claim 2 , wherein the threonine is mutated to an alanine.
6. The method of claim 2 , wherein the threonine is mutated to a tryptophan.
7. The method of claim 1 , wherein mutating includes mutating a threonine at a position corresponding to amino acid 252 relative to the E. coli leucyl-tRNA synthetase numbering to another amino acid and mutating an aspartic acid at a position corresponding to amino acid 342 relative to the E. coli leucyl-tRNA synthetase numbering to alanine.
8. The method of claim 1 , wherein mutating includes mutating a threonine at a position corresponding to amino acid 252 relative to the E. coli leucyl-tRNA synthetase numbering to another amino acid and mutating an aspartic acid at a position corresponding to amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering to an alanine.
9. The method of claim 1 , wherein mutating includes mutating a threonine at a position corresponding to amino acid 252 relative to the E. coli leucyl-tRNA synthetase numbering to an amino acid from the group consisting of alanine, tyrosine, and phenylalanine and mutating an aspartic acid at a position corresponding to amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering to any amino acid.
10. The method of claim 1 , wherein mutating includes mutating a threonine at a position corresponding to amino acid 252 relative to the E. coli leucyl-tRNA synthetase numbering to an amino acid from the group consisting of alanine, tyrosine, and phenylalanine and mutating an aspartic acid at a position corresponding to amino acid 342 relative to the E. coli leucyl-tRNA synthetase numbering to any amino acid.
11. The method of claim 1 , wherein mutating includes mutating a threonine at a position corresponding to amino acid 252 relative to the E. coli leucyl-tRNA synthetase numbering an aspartic acid at a position corresponding to amino acid 342 relative to the E. coli leucyl-tRNA synthetase numbering and mutating an aspartic acid at a position corresponding to amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering to alanine.
12. The method of claim 1 , wherein mutating includes mutating a threonine at a position corresponding to amino acid 252 relative to the E. coli leucyl-tRNA synthetase numbering an aspartic acid at a position corresponding to amino acid 342 relative to the E. coli leucyl-tRNA synthetase numbering and mutating an aspartic acid at a position corresponding to amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering to any amino acid.
13. A mutated leucyl-tRNA synthetase for aminoacylating at least one non-leucine amino acid onto a tRNA molecule comprising:
mutated leucyl tRNA synthetase having one to three amino acids mutated in a conserved editing active site region of a connective polypeptide 1 domain of leucyl tRNA synthetase, wherein the conserved editing active site region is selected from the group consisting of a threonine-rich region at a position corresponding to amino acids 247 to 257 relative to E. coli leucyl-tRNA synthetase numbering and a region surrounding a conserved aspartic acid corresponding to amino acid 345 including seven amino acids preceding amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering and combinations thereof, wherein mutation of the one to three amino acids inactivates editing activity of the mutated leucyl tRNA synthetase.
14. A method for aminoacylating non-leucine amino acids onto tRNA molecules comprising the steps of:
mutating one to three amino acids in a conserved editing active site region of a connective polypeptide 1 domain of a leucyl-tRNA synthetase, wherein the conserved editing active site region is selected from the group consisting of a threonine-rich region at a position corresponding to amino acids 247 to 257 relative to the E. coli leucyl-tRNA synthetase numbering and a region surrounding a conserved aspartic acid corresponding to amino acid 345 including seven amino acids preceding amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering, and combinations thereof, wherein mutating the one to three amino acids inactivates editing activity of the leucyl-tRNA synthetase and produces a mutated leucyl-tRNA synthetase that misaminoacylates non-leucine amino acids; and
aminoacylating a tRNA molecule with the mutated leucyl-tRNA synthetase in the presence of at least one non-leucine amino acid, thereby aminoacylating the non-leucine amino acid onto the tRNA molecule , wherein the non-leucine amino acid is an amino acid activated by the mutated leucyl-tRNA synthetase.
15. A mutated leucyl-tRNA synthetase for incorporating at least one non-leucine amino acid onto a tRNA molecule comprising:
a mutated leucyl tRNA synthetase having one to three amino acids mutated in a conserved editing active site region of a connective polypeptide 1 domain of leucyl tRNA synthetase, wherein the conserved editing active site region is selected from the group consisting of a threonine-rich region at a position corresponding to amino acids 247 to 257 relative to the E. coil leucyl-tRNA synthetase numbering and a region surrounding a conserved aspartic acid corresponding to amino acid 345 including seven amino acids preceding amino acid 345 relative to the E. coil leucyl-tRNA synthetase numbering, and combinations thereof, wherein mutation of the one to three amino acids inactivates editing activity of the mutated leucyl tRNA synthetase and produces a mutated leucyl-tRNA synthetase that misaminoacylates non-leucine amino acids.
16. The mutated leucyl-tRNA synthetase of claim 13 , wherein the mutated leucyl-tRNA synthetase has altered specificity for a cognate amino acid.
17. The mutated leucyl-tRNA synthetase of claim 13 , wherein the mutated leucyl-tRNA synthetase has altered specificity for a non-leucine amino acid.
18. The mutated leucyl-tRNA synthetase of claim 15 , wherein the mutated leucyl-tRNA synthetase has altered specificity for a cognate amino acid.
19. The method of claim 14 , wherein mutating includes mutating an aspartic acid to an alanine at a position corresponding to position 345 relative to the E. coli leucyl-tRNA synthetase numbering.
20. The method of claim 14 , wherein mutating includes mutating an aspartic acid to any amino acid at a position corresponding to position 345 relative to the E. coli leucyl-tRNA synthetase numbering.
21. The method of claim 14 , wherein mutating includes mutating an aspartic acid to any amino acid at a position corresponding to amino acid position 342 relative to the E. coli leucyl -tRNA synthetase numbering.
22. The method of claim 14 , wherein mutating includes mutating an aspartic acid at a position corresponding to amino acid position 342 relative to the E. coli leucyl-tRNA synthetase numbering and an aspartic acid to alanine at a position corresponding to amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering.
23. The method of claim 14 , wherein mutating includes mutating an aspartic acid at a position corresponding to amino acid position 342 relative to the E. coli leucyl-tRNA synthetase numbering and an aspartic acid at a position corresponding to amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering to any amino acid.
24. The mutated leucyl-tRNA synthetase of claim 13 , wherein the mutated leucyl tRNA synthetase aminoacylates the non-leucine amino acids on a tRNA molecule.
25. A mutated leucyl-tRNA synthetase for aminoacylating at least one non-leucine amino acid onto a tRNA molecule comprising:
a mutated leucyl tRNA synthetase having one to three amino acids mutated in a conserved editing active site region of a connective polypeptide 1 domain of leucyl tRNA synthetase, wherein the conserved editing active site region is selected from the group consisting of a threonine-rich region at a position corresponding to amino acids 247 to 257 relative to the E. coli leucvl-tRNA synthetase numbering and a region surrounding a conserved aspartic acid corresponding to amino acid 345 including seven amino acids preceding amino acid 345 relative to the E. coli leucyl-tRNA synthetase numbering, and combinations thereof, wherein mutation of the one to three amino acids inactivates editing activity of the mutated leucyl tRNA synthetase and produces a mutated leucyl-tRNA synthetase that misaminoacylates non-leucine amino acids.
26. The mutated leucyl-tRNA synthetase of claim 25 , wherein the mutated leucyl-tRNA synthetase has altered specificity for a cognate amino acid.
27. The mutated leucyl-tRNA synthetase of claim 25 , wherein the mutated leucyl-tRNA synthetase has altered specificity for a non-leucine amino acid.
28. The mutated leucyl-tRNA synthetase of claim 25 , wherein the mutated leucyl tRNA synthetase is from the group consisting of a derivative, natural, synthetic analog, engineered enzyme, mimetic, single mutant, multiple mutant, mutant with deletions, chimeric molecule, versions that are cognate to other amino acids, and combinations thereof
29. The mutated leucyl-tRNA synthetase of claim 25 , wherein the mutated leucyl tRNA synthetase incorporates the non-leucine amino acids on a tRNA molecule.